184 filings
6-K
ADXN
Addex Therapeutics Ltd
6 Jun 24
Current report (foreign)
6:00am
6-K
ADXN
Addex Therapeutics Ltd
5 Jun 24
Addex Convenes Annual General Meeting 2024
6:05am
6-K
ADXN
Addex Therapeutics Ltd
29 Apr 24
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
6:05am
424B3
ADXN
Addex Therapeutics Ltd
24 Apr 24
Prospectus supplement
4:00pm
EFFECT
ADXN
Addex Therapeutics Ltd
23 Apr 24
Notice of effectiveness
12:15am
POS AM
fh3l7pqa
18 Apr 24
Prospectus update (post-effective amendment)
4:00pm
6-K
ogzmoip9
18 Apr 24
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
6:05am
6-K
pjvrw bh53kc
3 Apr 24
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
6:05am
424B5
3ajk x9pd2nyy7brz
30 Jan 24
Prospectus supplement for primary offering
5:00pm
6-K
dap7qdpqc0aq4l
30 Jan 24
Current report (foreign)
4:58pm
6-K/A
4209q
21 Dec 23
Current report (foreign) (amended)
6:00am
6-K
4n83c b2yf2zvhp6zp
20 Dec 23
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
6:05am
6-K
5m4zw7cugwi51xe r3
14 Dec 23
Addex Creates Treasury Shares
6:05am
424B3
5kcabj1
30 Nov 23
Prospectus supplement
4:00pm
EFFECT
py8m6x r6jpuj7
30 Nov 23
Notice of effectiveness
12:15am
POS AM
702lsm4uc8ba4k
29 Nov 23
Prospectus update (post-effective amendment)
6:27am
6-K
jvihzslo fzb
29 Nov 23
Current report (foreign)
6:00am
6-K
yvphopoozq4yl8g8qm
28 Nov 23
Addex Convenes Extraordinary General Meeting
6:05am
6-K
awxrb0op73w
14 Nov 23
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
6:05am